/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the initial.
/PRNewswire/ - enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by.
/PRNewswire/ - enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by.
In the current study, DDR1 has been identified as a cancer-associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues.
29 As an important receptor, DDR1 can bind all types of collagens and could influence their signalling upon collagen stimulation.
30 It has been reported that the phosphorylation of DDR1 could activate the WNT/β-catenin and AKT/mTOR signaling to drive cancer cell metastasis and progression.
31,32 We observed that pY792 DDR1, the active form of DDR1, was upregulated by COL5A2 overexpression in HCT116 and SW620 cells (Figure 4D).
These observations indicate that
COL5A2 expression upregulates WNT/β-catenin and PI3K/mTOR signaling via binding DDR1 with phosphorylation and activation of this receptor, which might contribute to CRC tumorigenesis or progression.
F. Hoffmann-La Roche Ltd: Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
25.8
DFS, HR
(95% CI)
(0.19-0.60)
About bladder cancer and muscle-invasive urothelial cancer
In 2018, there were over half a million new cases of bladder cancer diagnosed globally, with approximately 200,000 deaths from the disease.
4 Urothelial cancer is the most common type of bladder cancer, accounting for about 90-95% of all cases.
5 MIUC is a type of urothelial cancer that has spread into the muscle of the bladder, ureter or renal pelvis.
6 Approximately 25% of new cases of bladder cancer are diagnosed with muscle-invasive disease,